Our findings confirm 1) that YM155 is a drug candidate for neuroblastoma including therapy-refractory disease with the majority of cell lines being sensitive to clinically achievable YM155 concentrations and 2) that ABCB1 is an important determinant of YM155 sensitivity. Here, ABCB1 is linked to neuroblastoma.